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Discrete variables n (%)
Wilcoxon rank
sum p-value
mean rank of
total costs
Gender (male) 32 (37.2%) .526
NYHA III, IV 62 (72.1%) .472
Atrial fibrillation 19 (22.1%) .735
Carotid disease 4 (4.7%) .335
CAD 42 (48.8%) .140
Porcelain aoreta 5 (5.8%) .789
PVD 9 (10.5%) .239
Diabetes 21 (24.4%) .591
Pulmonary hypertension 14 (16.3%) .037 56.21 with
pht.
41.03 without
pht.
Mediastinal radiation 6 (7.0%) .919
Hyperlipidemia 29 (33.7%) .004 32.59 with hl.
49.05 without
hl.
COPD 14 (16.3%) .194
Renal failure 11 (12.8%) .781
Angina 18 (20.9%) .531
Previous MI 10 (11.6%) .215
Previous stroke-TIA 2 (2.3%) .626
Previous pacemaker 2 (2.3%) .071 12 with pm.
44.25 without
pm.
Previous CABG 25 (29.1%) .898
Previous valve surgery 4 (4.7%) .743
Previous PCI 17 (19.8%) .371
Year of intervention .091
2007-2009 43 (50.0%) 47.77
2010 20 (26.7%) 44.12
2011 23 (23.3%) 32.44
Continuous variables Mean (sd) Spearman rho’s
p-value
age (years) 81.8 (6.6) .989
log euroscore 25.6 (15.2) .559
AVA (cm2) 0.6 (0.15) .556
Mean grad (mmHg) 25.2 (17.0) .824
LVEF (%) 59.4 (12.7) .899
Conclusions: Total hospitalisation costs of TAVI amount to about €40,000. Main cost
driver is length of stay and valve cost. Costs decrease marginally over time. Most patient
characteristics are not significantly related to total hospitalisation costs.
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Background: For currently available percutaneous aortic valve prosthesis, device design
limitations and potential misplacement can lead to significant aortic regurgitation, which
can result in severe complications and have an impact on long-term survival. The Direct
Flow Medical (DFM) valve is repositionable and retrievable and has non metallic
inflatable cuff with a conformable design that results in better valve sealing. Compared to
the first generation, the new 18F prosthesis, has a smaller profile, increased radial force
and better handling. We report the first series of high risk patients who received the 18F
DFM transfemoral prosthesis for severe aortic stenosis. Aim of the study was to test the
safety and performance of the 18F Direct Flow Medical valve in high risk patients with
severe aortic stenosis.
Methods: In this prospective, multicenter, non-randomized clinical trial 100 symptomatic
patients with severe aortic stenosis and a logistic Euro-SCORE  20% will be enrolled.
The primary endpoint is freedom from all-cause mortality @ 30 days, secondary
endpoints were device success and safety according to the VARC criteria. Data are
monitored and events adjudicated by independent committees (DMC, CEC). All echo-
cardiograms and angiograms were assessed by an independent Core Laboratory.
Results: The study started in January 2012 in 5 centers in Europe. Five additional centers
will follow. As of May 2012, 25 patients have been enrolled (mean age 84.9 y, 76-95 yrs,
mean logistic Euro-Score 27.9%, mean STS 11%). The primary endpoint of freedom from
death at 30 days was achieved in all 25 patients. The valve was retrieved and reimplanted
in 4 patients. At present, 10 pts had core lab evaluation, revealing a mean transvalvular
gradient at 30 days of 11 mmHg. There was no aortic regurgitation in 8 pts and 2 had trace
aortic regurgitation.
Conclusions: The 18F DFM valve can be safely implanted, repositioned and, if
necessary retrieved in high risk patients with severe aortic stenosis. Preliminary results
suggest excellent hemodynamic performance with abolishing significant aortic regurgi-
tation. The results of the completed study will be available at TCT 2012.
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Background: The Direct Flow Medical (DFM) valve is repositionable and retrievable.
The non metallic inflatable and conformable design of the valve results in better sealing
but in less radial force which may have an impact on stability and valve function over
time. Aim of the study was to evaluate the 4-year clinical and echocardiographic outcome
of the first generation 22F-DFM percutaneous aortic valve.
Methods: From 2007 to 2008 31 symptomatic high-risk for surgery patients (mean age
824y) with severe aortic stenosis and a mean logistic EuroSCORE of 297% were the
subject of this analysis. Clinical, echocardiographic and hemodynamic follow-up were
obtained during 4 years.
Results: Survival rates were 81%, 69%, 60%, and 54% at 1,2,3,4 years, respectively. At
4 years, 83% of the patients, who survived, were in NYHA-class I, 17% in class II.
Echocardiography revealed a significant decrease of the mean gradient from baseline
(49.113.8 mmHg) to 30 days (19.16.8 mmHg, p  0.001), which remained stable
over 4 years. At 4-year follow-up, 80% of the patients had no aortic regurgitation, 20 %
had trace aortic regurgitation.
Conclusions: In this preliminary series, the first generation of the nonmetallic, reposi-
tionable and retrievable 22F-DFM valve was associated with acceptable clinical outcome
and stable hemodynamic performance with no aortic regurgitation in the majority of
patients.
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Background: Percutaneous transcatheter aortic valve implantation (TAVI) is associated
with favorable safety and efficacy outcomes in older patients at high risk for surgical AV
replacement. Health Related Quality of life (HRQoL) can be at least, if not more,
important than quantity of life in an elderly patient population, often frail, and with
multiple comorbidities. The Medtronic CoreValve ADVANCE is a prospective, multi-
center, 100% monitored study evaluating “real world” patients with severe aortic stenosis
treated with the CoreValve System (Medtronic, Minneapolis, MN). The HRQoL
measures collected in the ADVANCE study represents the largest, rigorously reported
cohort of HRQoL findings in the TAVI literature.
Methods: From March 2010 to July 2011, the ADVANCE study enrolled 1015 patients
at 44 experienced centers in Western Europe, Asia, and South America. HRQoL was
evaluated using the SF-12 and the EQ-5D, 2 general validated questionnaires. Results of
the measurements at baseline, 1 and 6 months are reported.
Results: Baseline clinical characteristics were: 50.6% female, age 81.16.4 y, log
EuroSCORE 19.212.4, 79.6% NYHA Class III/IV, 22.6% COPD, 21.4% prior CABG,
14.6% renal failure, and 12.9% cerebrovascular disease. Compared with baseline,
physical and mental summary score (PCS and MCS) measures and the EQ-5D index
significantly improved at 1 and 6 months.
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